Loading...
•
Jun 30, 2022
Insulet Q2 2022 Earnings Report
Reported a revenue increase of 14% year-over-year (18% constant currency).
Key Takeaways
Insulet reported strong second-quarter results with revenue exceeding guidance, driven by growth in Omnipod, particularly in the U.S., and highlighted strategic advancements including the full market release of Omnipod® 5 in the U.S.
Second quarter revenue increased by 13.8% to $299.4 million, or 17.7% in constant currency.
U.S. Omnipod revenue increased by 30.5% to $196.4 million.
Gross margin decreased by 580 basis points to 63.6%.
The company launched the Omnipod® 5 Automated Insulin Delivery System in the U.S. through retail pharmacies.
Revenue by Segment
Forward Guidance
The Company expects revenue growth of 17% to 20% for the quarter ending September 30, 2022.
Positive Outlook
- Total Omnipod revenue growth of 18% to 21%.
- U.S. Omnipod revenue growth of 24% to 27%.
- International Omnipod revenue growth of 7% to 10%.
- Drug Delivery revenue decline of (14)% to (5)%.
- Operating margin, excluding the impact from legal and CEO transition costs, to be high-single digits.
Challenges Ahead
- Operating margin is expected to be lower year-over-year.
- Higher manufacturing costs.
- Macro environment creating inflationary pressures.
- Foreign exchange pressures.
- Drug Delivery revenue decline of (14)% to (5)%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...